Last edition
News about "US FDA OAI status"
Aurobindo Pharma's Eugia Unit I Receives US FDA Warning Letter
Aurobindo Pharma’s Eugia Pharma Unit I receives a US Food and Drug Administration (FDA) Warning Letter following OAI status, with no impact on existing US supplies.
US FDA OAI Status | 14/08/2026 | By News Bureau | 130
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members